Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to issue first quarter fiscal year 2021 financial results Tuesday, Feb. 16.

Agilent to Webcast First-Quarter Fiscal Year 2021 Financial Results Presentation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of MassHunter Workstation Plus 11.0, MassHunter Networked Workstation 11.0, and MassHunter BioConfirm. The latest revision of these software enables data integrity consistent with the regulatory requirements from the US FDA and EU EMEA guidance, providing user management, checksums, tamper detection, and audit trails for MassHunter Acquisition, Quantitative Analysis, and MassHunter BioConfirm.

Agilent Announces Enhanced Mass Spectrometry and Automation Software Solutions to Support Regulatory Compliance Guidelines

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent names Allison Ballmer senior vice president of Strategy and Corporate Development.

Agilent Names Allison Ballmer Senior Vice President of Strategy and Corporate Development

Baxter

Centene

Veeva Systems

Walgreens

According to the GuruFocus All-in-One Screener as of Jan. 15, the following Health Care stocks are popular among gurus.

5 Health Care Stocks Gurus Are Buying

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Why Is Agilent (A) Up 2.4% Since Last Earnings Report?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. The company also announced that it has register

Agilent Receives Approval for GenetiSure Dx Postnatal Assay in Japan

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces investor webcasts.

Agilent Announces Webcasts for Investment Community

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that both the NanoDis System and the innovative new style polychromator in the 5800 and 5900 ICP-OES have received Innovation Awards from The Analytical Scientist. The recently launched NanoDis System utilizes cross-flow filtration—a concept traditionally used in industrial process chemistry—combined with conventional dissolution instruments to enable nanoparticle dissolution testing. Along with the introd

Agilent Receives Multiple Innovation Awards

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent releases 2019 corporate social responsibility report.

Agilent Releases 2019 Corporate Social Responsibility Report

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) has honored Prof. Anurag Rathore, a scientist at the Indian Institute of Technology (IIT) Delhi, with an Agilent Thought Leader Award, for his contributions to the field of biopharmaceutical research and his work with advanced methods for molecular characterization of biosimilars. The 2020 award includes a grant to support research personnel and Agilent instrumentation including a 6545XT AdvanceBio LC/Q-TOF, a Bravo Autom

Agilent Presents Thought Leader Award to IIT Delhi Scientist Professor Anurag Rathore

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its clinical informatics platform Alissa Interpret has been adopted by the North West Genomic Laboratory Hub (NW GLH) based in Manchester and Liverpool, part of Manchester University NHS Foundation Trust, England. The NW GLH and its partners are responsible for delivering genomic testing across the whole of the North West. Alissa Interpret, which enables clinical genetics labs to standardize and automate v

Agilent Announces Alissa Interpret Selected by North West Genomic Laboratory Hub for Clinical Genomic Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a new ICP-MS instrument, the Agilent 7850 ICP-MS System, that provides new smart tools to minimize common time traps that can affect ICP-MS analysis workflows. Building on decades of innovation, the 7850 ICP-MS combines market-leading performance with new smart software features that bring advanced capabilities to the routine ICP-MS laboratory. The new 7850 provides solutions that enable customers to be mo

Agilent Announces New, Innovative 7850 ICP-MS System

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and confidently. Developed by Agilent – a worldwide leader in developing and commercializing diagnostic products – this training program incorporates Agilent's unique expertise in companion diagnostics and partnership with top pharmaceutical companies. Biomarker testi

Agilent Announces Launch of Global Biomarker Pathologist Training Program

Agilent Technologies' (A) fiscal fourth-quarter results reflect growth in all the segments and regions served.

Agilent's (A) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Agilent Technologies Inc. (A) CEO Mike McMullen on Q4 2020 Results - Earnings Call Transcript

Shares of Agilent Technologies (NYSE:A) fell 2.53% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 10.11% over the past year to $0.98, which beat the estimate of $0.93.

Agilent Technologies: Q4 Earnings Insights

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent reports fourth-quarter and fiscal year 2020 financial results; initiates fiscal 2021 guidance.

Agilent Reports Fourth-Quarter and Fiscal Year 2020 Financial Results; Initiates Fiscal 2021 Guidance

American Equity Investment Life

Aflac

Capital City Bank Group

Core-Mark Holding Company

Matthews International

McCormick

Merck

Motorola Solutions

NIKE

Royal Gold

Spire

First Financial

In this article series, we provide a weekly summary of dividend changes. A summary table provides relevant data and key statistics of dividend increases.

Dividend Changes: November 14-20, 2020

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of the NanoDis System for nanoparticle dissolution testing. Combining Agilent instrumentation and software to enable customers to meet 21 CFR Part 11 and other regulations through its application, the new NanoDis System delivers a dedicated workflow that is automatable and auditable. Designed in collaboration with Dr. Emre Türeli from nanoparticle manufacturer MyBiotech GmbH, the NanoDis S

Agilent Launches New NanoDis System for Nanoparticle Dissolution Testing

Agilent (A) hikes dividend to 19.4 cents per share in a bid to reward shareholders.

Agilent (A) Hikes Dividend to 19.4 Cents, Rewards Shareholders

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent increases the company's quarterly dividend to 19.4 cents per share of common stock, reflecting an 8% increase over the previous quarter.

Agilent Increases Cash Dividend to 19.4 Cents Per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced professors Carl H. June, MD, and Michael Milone, MD, Ph.D., as recipients of an Agilent Thought Leader Award. Both scientists are being recognized for their joint contributions to the field of CAR T-cell mediated cancer immunotherapy, having codeveloped tisagenlecleucel (Kymriah™), the first cell and gene therapy product approved by the US FDA. The award will focus on defining standards for the design, val

Agilent Presents Thought Leader Award to Drs. Carl H. June and Michael Milone

Agilent Technologies (A) gets FDA Approval for PD-L1 IHC 22C3 pharmDx assay, thereby further strengthening presence in the companion diagnostics market.

Agilent Gets Expanded FDA Approval for pharmDX Assay in U.S.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer (TNBC) for treatment with KEYTRUDA® (pembrolizumab). PD-L1 expression is a critical biomarker for response to anti-PD-1 therapies such as KEYTRUDA. The expanded use of PD-L1 IHC 22C3 pharmDx strengthens the ability of pathologists to identify patients who may be eligible f

Agilent Receives Expanded FDA Approval for PD-L1 IHC 22C3 pharmDx in Triple-Negative Breast Cancer

In this article we are going to use hedge fund sentiment as a tool and determine whether Agilent Technologies Inc. (NYSE:A) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of news stories covering failed hedge fund investments and it is a fact that hedge funds' picks don't beat the market 100% of the time, but their consensus picks have historically done very well and have outperformed the market after adjusting for risk.

News for Agilent Technologies Stock (A)